Project PERCH brings together 18 European countries and 34 partner organizations with the objective of contributing to the implementation of Europe’s Beating Cancer Plan. PERCH aligns with the World Health Organization’s (WHO) “90-70-90” strategy, aiming to achieve at least 90% HPV vaccination coverage among girls, and potentially boys, by the age of 15 years.
Project objectives are:
Subscribe to PERCH newsletter and get the latest updates from European Partnership to Contrast HPV
On June 21, the Council of the European Union took an important step in the fight against cancer by adopting a Council Recommendation on vaccine-preventable cancers. This recommendation, originally proposed
Work Package 7 (WP) of the PERCH project is dedicated to improving the communication skills of healthcare professionals regarding the human papillomavirus (HPV) vaccine. By improving communication between healthcare professionals,
On June 21, the Council of the European Union took an important step in the fight against cancer by adopting a Council Recommendation on vaccine-preventable cancers. This recommendation, originally proposed
Work Package 7 (WP) of the PERCH project is dedicated to improving the communication skills of healthcare professionals regarding the human papillomavirus (HPV) vaccine. By improving communication between healthcare professionals,
On June 21, the Council of the European Union took an important step in the fight against cancer by adopting a Council Recommendation on vaccine-preventable cancers. This recommendation, originally proposed by the European Commission on January 31, is an important part of Europe’s Beating Cancer Plan. It aims to improve
Work Package 7 (WP) of the PERCH project is dedicated to improving the communication skills of healthcare professionals regarding the human papillomavirus (HPV) vaccine. By improving communication between healthcare professionals, children/adolescents and their parents, WP7 aims to increase confidence in the HPV vaccine. The first task was a comprehensive assessment
Work Package 6 (WP6) deals with “Improving knowledge and awareness to increase vaccine uptake in target communities”. Its general objective is to improve knowledge and awareness about HPV-related diseases and their prevention among adolescent girls and boys and to educate the target groups about the benefits of vaccination for individual
Recently an editorial article “Linkage of individual-patient data confirms protection of prophylactic human papillomavirus vaccination against invasive cervical cancer,” was published in the “JNCI: Journal of the National Cancer Institute”. It has provided an overview of the excellent effectiveness of the human papillomavirus (HPV) vaccine in preventing invasive cervical cancer,
The PERCH WP2 meeting produced valuable results On 24 and 25 April 2024, health and communication experts from the PERCH partner countries met in person in Ljubljana and via Zoom. The main purpose of the PERCH WP2 meeting was to facilitate discussions and collaboration between the participating countries on the
On 17 November 2023 PERCH met students, teachers and parents from some schools in Basilicata participating in the Project to address aspects relating to HPV and its prevention.
The meetings will also continue in other Italian regions involved in the PERCH project.
On 13 November 2023 PERCH met students, teachers and parents from some schools in Puglia participating in the Project to address aspects relating to HPV and its prevention.
The meetings will also continue in other Italian regions involved in the PERCH project.
On 10 November 2023 PERCH met students, teachers and parents from some schools in Piemonte participating in the Project to address aspects relating to HPV and its prevention.
The meetings will also continue in other Italian regions involved in the PERCH project.
Subscribe to PERCH newsletter and get the latest updates from European Partnership to Contrast HPV
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not re!ect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.
